Compare MTW & RCKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MTW | RCKT |
|---|---|---|
| Founded | 1902 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Construction/Ag Equipment/Trucks | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 479.6M | 428.6M |
| IPO Year | N/A | N/A |
| Metric | MTW | RCKT |
|---|---|---|
| Price | $13.54 | $3.65 |
| Analyst Decision | Sell | Buy |
| Analyst Count | 4 | 14 |
| Target Price | $10.25 | ★ $29.12 |
| AVG Volume (30 Days) | 220.6K | ★ 2.0M |
| Earning Date | 02-11-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.58 | N/A |
| Revenue | ★ $2,159,800,000.00 | N/A |
| Revenue This Year | $0.28 | N/A |
| Revenue Next Year | $6.14 | N/A |
| P/E Ratio | $8.58 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.06 | $2.19 |
| 52 Week High | $14.33 | $11.45 |
| Indicator | MTW | RCKT |
|---|---|---|
| Relative Strength Index (RSI) | 60.01 | 52.98 |
| Support Level | $13.69 | $3.47 |
| Resistance Level | $14.33 | $3.98 |
| Average True Range (ATR) | 0.47 | 0.23 |
| MACD | 0.05 | 0.01 |
| Stochastic Oscillator | 67.38 | 44.93 |
Manitowoc Co Inc provides engineered lifting solutions. It designs and manufactures mobile telescopic cranes, tower cranes, lattice-boom crawler cranes, and boom trucks. It offers products under brand names such as Grove, Manitowoc, National Crane, Potain, Shuttlelift, and Manitowoc Crane Care. Its crane products serve dealers, rental companies, contractors, and government entities in diverse markets, including energy production/distribution and utility, petrochemical and industrial, infrastructure, and commercial/residential construction. Manitowoc has three reportable segments: the Americas, Europe and Africa, and the Middle East and Asia-Pacific. The Americas segment generates the majority of the revenue for the company.
Rocket Pharmaceuticals Inc is a late-stage biopharmaceutical company. It is focused on the development of gene therapies for rare and devastating pediatric diseases. The pipeline products of the company include RP-A501 for Danaon Disease, RP-L102 for Fanconi Anemia, RP-L201 for Leukocyte Adhesion, RP-L301 for Pyruvate Kinase Deficiency, and RP-L401 for Infantile Malignant Osteopetrosis. The Company has one reportable segment related to R&D and commercial readiness of its gene therapies.